In a subsequent study [59], the analysis of PLCB1 expression in 18 high-risk MDS patients undergoing Azacytidine treatment showed that changes in gene expression preceded clinical improvements or worsening by about two months. Here, PLCB1 is linked to myelodysplastic syndrome.